Project Grant R41NS115460

Teliatry Inc. received a $768,138 project grant award from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering to develop a minimally invasive, single incision, rechargeable spinal cord stimulation system for chronic pain management. The grant was awarded under the Discovery and Applied Research for Technological Innovations to Improve Human Health program. Through this award, Teliatry will engineer the world's smallest (0.75cc), most cost-effective...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,505,537 to The Leland Stanford Junior University to develop a focused ultrasound (FUS) device for noninvasive, peripheral nerve blockade to manage acute pain. The goal is to provide an alternative to opioids and current peripheral nerve block techniques, which have significant limitations in acute pain management. The...

This federal Project Grant award of $6,947,232.00 was provided by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The objective is to develop a novel combined device/drug treatment called "SmartStim" for chronic pain, which utilizes electrical stimulation and localized drug release to selectively block sensitized nociceptive afferents, especially C-fiber...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,522,833 Project Grant to The Leland Stanford Junior University to conduct a mechanistic randomized clinical trial investigating the central and peripheral nervous system mechanisms of pain relief induced by peripheral nerve stimulation (PNS) for the treatment of refractory chronic neuropathic pain. The 3-year study, funded under the NIH HEAL Initiative's CFDA 93.279 Drug Abuse and Addiction Research Programs, aims...

This SBIR Phase I Project Grant, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is focused on developing a novel minimally invasive spinal cord stimulation (SCS) lead and procedure. The $304,259 award to Backstop Neural, Inc. will support the development of an 8-channel shape memory polymer-based paddle lead that can be molded into a compact configuration for minimally invasive introduction through a needle, and then...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high-frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The funded project aims to create an HF-TSMS tool that can target neural pathways involved in...

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, awarded a $3,000,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Alcamena Stem Cell Therapeutics, LLC to develop a novel, non-opioid cell and tissue-permeable peptide therapeutic for epigenetic reprogramming of neuropathic pain. The award will support preclinical safety and tolerability studies for the company's lead therapeutic candidate, ASCT-83,...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $5,336,602 to the University of Connecticut to develop an implantable, degradable drug delivery device for non-opioid post-surgical pain management. The key objectives are to: 1) localize treatment to simplify delivery and avoid systemic toxicity, 2) achieve long-duration release to span the duration of post-operative pain...

This Cooperative Agreement award of $1,278,689 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop an automated Neonatal Pain Monitoring System (NPMS) and pain management protocol to objectively measure and minimize postoperative pain in newborns. The project has two key objectives: 1) Develop and validate AI-driven neonatal pain biomarker signatures and an automated NPMS to continuously...

This $499,863 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research by Function Therapeutics Inc. on a new class of small molecule compounds called Parmodulins for the treatment of neuropathic pain. The research aims to investigate the use of Parmodulins, which can modulate the signaling of the protease-activated receptor 1 (PAR1), to address neuropathic pain from...